Comparison of abdominal MRI with diffusion-weighted imaging to 68Ga-DOTATATE PET/CT in detection of neuroendocrine tumors of the pancreas

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 40, Issue 6, 2013, Pages 897-907

  Schmid Tannwald, Christine ^a   Schmid Tannwald, Christoph M ^a   Morelli, John N ^b   Neumann, Ralph ^a   Haug, Alexander R ^a   Jansen, Nathalie ^a   Nikolaou, Konstantin ^a   Schramm, Nicolai ^a   Reiser, Maximilian F ^a   Rist, Carsten ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

Author keywords

Abdominal MRI; Diffusion weighted imaging; Pancreatic neuroendocrine tumors

Indexed keywords

DOTATATE GA 68; GADOXETIC ACID; GALLIUM 68; TETRAXETAN; UNCLASSIFIED DRUG; 68GA DOTATATE; 68GA-DOTATATE; ORGANOMETALLIC COMPOUND;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER DIAGNOSIS; CANCER PATIENT; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; DIFFUSION WEIGHTED IMAGING; FEMALE; HUMAN; INTERMETHOD COMPARISON; LIVER METASTASIS; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREATIC NEUROENDOCRINE TUMOR; RADIOLOGIST; RETROSPECTIVE STUDY; VERY ELDERLY; ABDOMEN; COMPARATIVE STUDY; IMAGE PROCESSING; NEUROENDOCRINE TUMOR; OBSERVER VARIATION; PANCREAS TUMOR; PATHOLOGY; REPRODUCIBILITY; STATISTICAL MODEL; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS;

ABDOMEN; ADULT; AGED; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; MODELS, STATISTICAL; NEUROENDOCRINE TUMORS; OBSERVER VARIATION; ORGANOMETALLIC COMPOUNDS; PANCREATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES;

EID: 84891707068     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2371-5     Document Type: Article

References (37)

1. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-72.
2. Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P, et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology 2012;95:98-119.
3. Falconi M, Bartsch DK, Eriksson B, Klöppel G, Lopes JM, O'Connor JM, et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology 2012;95:120-34.
4. Oberg K. Pancreatic endocrine tumors. Semin Oncol 2010;37:594-618.
5. Auernhammer CJ, Göke B. Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin. Gut 2011;60:1009-21.
6. Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009;27:4656-63.
7. Hardie AD, Naik M, Hecht EM, Chandarana H, Mannelli L, Babb JS, et al. Diagnosis of liver metastases: value of diffusion-weighted MRI compared with gadolinium-enhanced MRI. Eur Radiol 2010;20:1431-41.
8. Schmid-Tannwald C, Agrawal G, Dahi F, Sethi I, Oto A. Diffusion-weighted MRI: role in detecting abdominopelvic internal fistulas and sinus tracts. J Magn Reson Imaging 2012;35:125-31.
9. Oto A, Yang C, Kayhan A, Tretiakova M, Antic T, Schmid- Tannwald C, et al. Diffusion-weighted and dynamic contrastenhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis. AJR Am J Roentgenol 2011;197:1382-90.
10. Oto A, Schmid-Tannwald C, Agrawal G, Kayhan A, Lakadamyali H, Orrin S, et al. Diffusion-weighted MR imaging of abdominopelvic abscesses. Emerg Radiol 2011;18:515-24.
11. Fattahi R, Balci NC, Perman WH, Hsueh EC, Alkaade S, Havlioglu N, et al. Pancreatic diffusion-weighted imaging (DWI): comparison between mass-forming focal pancreatitis (FP), pancreatic cancer (PC), and normal pancreas. J Magn Reson Imaging 2009;29:350-6.
12. Lee SS, Byun JH, Park BJ, Park SH, Kim N, Park B, et al. Quantitative analysis of diffusion-weighted magnetic resonance imaging of the pancreas: usefulness in characterizing solid pancreatic masses. J Magn Reson Imaging 2008;28:928-36.
13. Anaye A, Mathieu A, Closset J, Bali MA, Metens T, Matos C. Successful preoperative localization of a small pancreatic insulinoma by diffusion-weighted MRI. JOP 2009;10:528-31.
14. Brenner R, Metens T, Bali M, Demetter P, Matos C. Pancreatic neuroendocrine tumor: added value of fusion of T2-weighted imaging and high b-value diffusion-weighted imaging for tumor detection. Eur J Radiol 2012;81:e746-9.
15. Papotti M, Bongiovanni M, Volante M, Allìa E, Landolfi S, Helboe L, et al. Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch 2002;440:461-75.
16. Versari A, Camellini L, Carlinfante G, Frasoldati A, Nicoli F, Grassi E, et al. Ga-68 DOTATOC PET, endoscopic ultrasonography, and multidetector CT in the diagnosis of duodenopancreatic neuroendocrine tumors: a single-centre retrospective study. Clin Nucl Med 2010;35:321-8.
17. De Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA, et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med 2002;32:133-40.
18. Kabasakal L, Demirci E, Ocak M, Decristoforo C, Araman A, Ozsoy Y, et al. Comparison of (68)Ga-DOTATATE and (68)Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2012;39:1271-7.
19. Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, et al. Differential uptake of (68)Ga-DOTATOC and (68)Ga- DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors. Recent Results Cancer Res 2013;194:353-71.
20. 68Ga- DOTATATE PET/CT. Radiologe 2010;50:349-54.
21. Scheidhauer K, Miederer M, Gaertner FC. PET-CT for neuroendocrine tumors and nuclear medicine therapy options. Radiologe 2009;49:217-23.
22. Rufini V, Baum RP, Castaldi P, Treglia G, De Gaetano AM, Carreras C, et al. Role of PET/CT in the functional imaging of endocrine pancreatic tumors. Abdom Imaging 2012;37:1004-20.
23. Bhate K, Mok WY, Tran K, Khan S, Al-Nahhas A. Functional assessment in the multimodality imaging of pancreatic neuroendocrine tumours. Minerva Endocrinol 2010;35:17-25.
24. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2000;284:3043-5.
25. Breeman WA, de Jong M, de Blois E, Bernard BF, Konijnenberg M, Krenning EP. Radiolabelling DOTA-peptides with 68Ga. Eur J Nucl Med Mol Imaging 2005;32:478-85.
26. 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2009;36:765-70.
27. 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging 2008;35:1431-8.
28. 18F-FDG. Cancer 2008;112:2447-55.
29. 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med 2010;51:1349-56.
30. Hayashi D, Tkacz JN, Hammond S, Devenney-Cakir BC, Zaim S, Bouzegaou N, et al. Gastroenteropancreatic neuroendocrine tumors: multimodality imaging features with pathological correlation. Jpn J Radiol 2011;29:85-91.
31. Haug AR, Rominger A, Mustafa M, Auernhammer C, Göke B, Schmidt GP, et al. Treatment with octreotide does not reduce tumor uptake of (68)Ga-DOTATATE as measured by PET/CT in patients with neuroendocrine tumors. J Nucl Med 2011;52:1679-83.
32. Bakir B, Salmaslio?lu A, Poyanli A, Rozanes I, Acunas B. Diffusion weighted MR imaging of pancreatic islet cell tumors. Eur J Radiol 2010;74:214-20.
33. 18F-DOPA PET for the assessment of NET patients. Nucl Med Commun 2008;29:415-7. doi:10.1097/MNM.0b013e3282ffd70d.
34. Naswa N, Sharma P, Kumar A, Nazar AH, Kumar R, Chumber S, et al. Gallium-68-DOTA-NOC PET/CT of patients with gastro enteropancreatic neuroendocrine tumors: a prospective single-center study. AJR Am J Roentgenol 2011;197:1221-8.
35. Kumar R, Sharma P, Garg P, Karunanithi S, Naswa N, Sharma R, et al. Role of (68)Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours. Eur Radiol 2011;21:2408-16.
36. 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors. Ann Surg 2010;252:850-6.
37. Giesel FL, Kratochwil C, Mehndiratta A, Wulfert S, Moltz JH, Zechmann CM, et al. Comparison of neuroendocrine tumor detection and characterization using DOTATOC-PET in correlation with contrast enhanced CT and delayed contrast enhanced MRI. Eur J Radiol 2012;81:2820-5.